RACGAP1 (Rac GTPase activating protein 1)

This study presents genetic evidence supportive of a causal contribution of RACGAP1 to LUAD, highlighting it as a promising prognostic biomarker and candidate therapeutic target. By delineating a RACGAP1-driven axis that coordinates survival signaling and suppresses tumor surveillance, our findings highlight RACGAP1 as a promising therapeutic target for novel adjuvant strategies.

Inhibition of RACGAP1 sensitized TNBC cells to ferroptosis by inhibiting CPT1A-mediated FA metabolism. Targeting RACGAP1 might be feasible strategy for TNBC management.

We integrated lactylation modification profiles with transcriptomic data from three murine liver regeneration datasets (GSE20426, GSE70593, GSE4528)...This work uniquely establishes lactylation as a metabolic-epigenetic bridge linking physiological regenerative pathways to oncogenesis. By leveraging liver regeneration models and machine learning, we propose the identified gene panel as dual-purpose biomarkers for HCC diagnosis and therapeutic targeting, offering new insights into the metabolic-epigenetic regulation of HCC.

Importantly, restoring HIF-1α expression partially reversed the phenotypic changes caused by RACGAP1 knockdown. In summary, our findings establish that RACGAP1 promotes malignant progression and confers cisplatin resistance in NPC by upregulating HIF-1α, suggesting the RACGAP1/HIF-1α axis as a promising therapeutic target to overcome chemoresistance.

This study offers comprehensive insights into ECT2's role in cancer biology through integrative bioinformatics analyses. The results advocate for ECT2 as a potential biomarker and therapeutic target in diverse malignancies, suggesting avenues for personalized oncology strategies.

This study identified CCNB1, MLPH, PSME1, and RACGAP1 as key genes associated with the comorbidity of breast cancer and depression.

The HRG and LRG suggested notable differences in sensitivity to 86 drugs such as AZD8186...The in vitro results were consistent with the results of bioinformatics analysis, indicating that the analysis results were reliable. This study identified 5 prognostic genes and a risk model, suggesting a fresh thought on the subsequent development of PCa related drugs.

The breast tumor stromal cells were suggested as the main source of the germline-associated genes. This study provides insights into the molecular mechanisms and pathways involved in germ cell transition in breast carcinoma.

Additionally, risk score was significantly higher in patients with advanced-stage and high-grade tumors. In conclusion, diagnostic biomarker candidates classifying HCC patients and healthy controls, and a novel prognostic gene signature predicting overall survival of HCC patients were identified by using machine learning approaches.

Mitotane, the medication licenced for ACC, has had mixed results...Paclitaxel and cisplatin were the central nodes within the drug-gene network...Network analysis shows fluorouracil and epirubicin target the ACC novel hub gene, HMMR. Fluorouracil was more effective due to its impact on M2 macrophage infiltration.

Further molecular mechanism studies revealed that RACGAP1 affects cytoskeleton recombination and extracellular matrix degradation by regulating Rho/ROCK signaling pathway, thus promoting tumor cell proliferation and metastasis. The application of thermal infrared medical examination technology showed that tumor cells with high expression of RACGAP1 showed higher temperature in thermal imaging, suggesting that RACGAP1 may be a potential marker in thermal infrared medical examination.

In conclusion, this study elucidated the biological function of RACGAP1 in promoting ccRCC progression, and revealed the regulatory mechanism of RACGAP1 in interfering with metabolic pathways from the perspective of multidimensional metabolomics. These findings will provide new targets and a theoretical basis for the treatment of RCC.